| dc.contributor.author | Asik E. | |
| dc.contributor.author | Akpinar Y. | |
| dc.contributor.author | Caner A. | |
| dc.contributor.author | Kahraman N. | |
| dc.contributor.author | Guray T. | |
| dc.contributor.author | Volkan M. | |
| dc.contributor.author | Albarracin C. | |
| dc.date.accessioned | 2019-11-24T20:39:02Z | |
| dc.date.available | 2019-11-24T20:39:02Z | |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 1743-5889 | |
| dc.identifier.uri | https://dx.doi.org/10.2217/nnm-2019-0132 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12513/2616 | |
| dc.description | PubMed ID: 31432749 | en_US |
| dc.description.abstract | Aim: To investigate the role of EF2K in BRCA1-mutated breast cancer. Materials & methods: We developed silica coated cobalt-ferrite (CoFe) nanoparticles for in vivo delivery of small interfering RNAs (siRNAs) into BRCA1-mutated breast cancer. Results: Expression of EF2K is highly upregulated in the majority (78.5%) of BRCA1-mutated patients and significantly associated with poor patient survival and metastasis. Silencing of EF2K reduced cell proliferation, migration and invasion of the cancer cells. In vivo therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained EF2K gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer. Conclusion: EF2K is a potential novel molecular target in BRCA1-mutated tumors and CoFe-based siRNA nanotherapy may be used as a novel approach to target EF2K. © 2019 © 2019 Future Medicine Ltd. | en_US |
| dc.description.sponsorship | Türkiye Bilimsel ve Teknolojik Araştirma Kurumu --This study has been supported by the Scientific and Technological Research Council of Turkey (TUBITAK) under the 2214-A International Research Fellowship for Doctoral Students. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. -- | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Future Medicine Ltd. | en_US |
| dc.relation.isversionof | 10.2217/nnm-2019-0132 | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | angiogenesis | en_US |
| dc.subject | BRCA1 | en_US |
| dc.subject | breast cancer | en_US |
| dc.subject | EF2 kinase | en_US |
| dc.subject | gene-silencing therapy | en_US |
| dc.subject | invasion | en_US |
| dc.subject | metastasis | en_US |
| dc.subject | migration | en_US |
| dc.subject | nanoparticles | en_US |
| dc.subject | PARP inhibitor | en_US |
| dc.title | EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer | en_US |
| dc.type | article | en_US |
| dc.relation.journal | Nanomedicine | en_US |
| dc.contributor.department | Kırşehir Ahi Evran Üniversitesi, Fen-Edebiyat Fakültesi, Kimya Bölümü | en_US |
| dc.identifier.volume | 14 | en_US |
| dc.identifier.issue | 17 | en_US |
| dc.identifier.startpage | 2315 | en_US |
| dc.identifier.endpage | 2338 | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
